ERBB2 and breast cancer: The obtained nanonuclear drug (68Ga-NP-mAb and 177Lu-NP-mAb) and nanoprobe can be moved into the lymph node metastasis via the delivery of lymphatic system, which developed a new theranostic strategy for lymphatic targeting used for near-infrared fluorescence (NIRF), single-photon emission computed tomography (SPECT), positron emission tomography (PET) and targeted radionuclide therapy (TRT) of HER2-positive breast cancer lymph node metastasis tumor in mice (Scheme 1).